Cost to insure Bristol-Myers debt hits highest since 2010


The cost to insure Bristol-Myers Squibb debt hit its highest point since 2010 on Thursday, following the announcement that the U.S. pharmaceutical company would acquire rival Celgene Corp in a deal worth $74 billion.